Venetoclax联合低剂量阿糖胞苷治疗不适合强化化疗的初治急性髓系白血病:Ⅲ期随机安慰剂对照试验中国队列结果
该研究为国际Ⅲ期随机双盲安慰剂对照试验VIALE-C的中国队列分析,入组15例不适合强化化疗的初治AML患者,随机接受Venetoclax+LDAC或安慰剂+LDAC。结果显示Venetoclax组死亡风险较安慰剂组下降38%(HR=0.62,95%CI 0.12-3.07),中位OS分别为9.0个月和4.1个月,CR/CRi率为33%对0%,安全性可管理。
要点
- 中国队列中Venetoclax+LDAC较安慰剂+LDAC死亡风险下降38%(HR=0.62)。
- 延长随访6个月分析中位OS为9.0个月对4.1个月。
- CR/CRi率为33%(3/9)对0%(0/6),安全性可管理。
核心结论
- Venetoclax联合LDAC在中国不适合强化化疗的初治AML患者中显示出有意义的疗效和可管理的安全性,与全球VIALE-C人群观察一致。
研究设计与样本
- 国际、随机、双盲、安慰剂对照Ⅲ期试验(VIALE-C)的中国队列分析。
- 全球入组211例患者,按2∶1随机接受Venetoclax+LDAC或安慰剂+LDAC,28天为1周期,LDAC第1-10天给药。
- 中国队列共15例(Venetoclax组9例,安慰剂组6例),中位年龄72岁(范围61-86岁)。
- 主要终点为总生存(OS),次要终点包括缓解率、无事件生存期及不良事件。
主要发现
- 与安慰剂组相比,Venetoclax组死亡风险下降38%(HR=0.62,95%CI 0.12-3.07)。
- 延长6个月随访的计划外分析显示,Venetoclax组中位OS为9.0个月,安慰剂组为4.1个月。
- CR率与CRi率分别为33%(3/9)和0%(0/6)。
- 最常见非血液学不良事件(Venetoclax组 vs 安慰剂组):低钾血症5/9 vs 4/6,呕吐4/9 vs 3/6,便秘2/9 vs 4/6,低白蛋白血症1/9 vs 4/6。
临床怎么用
- 对于不适合强化化疗的中国初治AML患者,可考虑Venetoclax联合LDAC作为治疗选择。
局限性
- 中国队列样本量小(Venetoclax组9例,安慰剂组6例),结果解释需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the safety and efficacy of venetoclax with low-dose cytarabine (LDAC) in Chinese patients with acute myeloid leukemia (AML) who are unable to tolerate intensive induction chemotherapy. Methods: Adults ≥ 18 years with newly diagnosed AML who were ineligible for intensive chemotherapy were enrolled in this international, randomized, double-blind, placebo-controlled trial. Globally, patients (n=211) were randomized 2∶1 to either venetoclax with LDAC or placebo with LDAC in 28-d cycles, with LDAC on days 1-10. The primary endpoint was OS; the secondary endpoints included response rates, event-free survival, and adverse events. Results: A total of 15 Chinese patients were enrolled (venetoclax arm, n=9; placebo arm, n=6) . The median age was 72 years (range, 61-86) . For the primary analysis, the venetoclax arm provided a 38% reduction in death risk compared with the placebo[hazard ratio (HR) , 0.62 (95%CI 0.12-3.07) ]. An unplanned analysis with an additional 6 months of follow-up demonstrated a median OS of 9.0 months for venetoclax compared with 4.1 months for placebo. The complete remission (CR) rates with CR with incomplete blood count recovery (CRi) were 3/9 (33%) and 0/6 (0%) , respectively. The most common non-hematologic adverse effects (venetoclax vs placebo) were hypokalemia[5/9 (56%) vs 4/6 (67%) ], vomiting[4/9 (44%) vs 3/6 (50%) ], constipation[2/9 (22%) vs 4/6 (67%) ], and hypoalbuminemia[1/9 (11%) vs 4/6 (67%) ]. Conclusion: Venetoclax with LDAC demonstrated meaningful efficacy and a manageable safety profile in Chinese patients consistent with the observations from the global VIALE-C population, making it an important treatment option for patients with newly diagnosed AML who are otherwise ineligible for intensive chemotherapy. 目的: 探讨Venetoclax联合低剂量阿糖胞苷(LDAC)在不能耐受强化诱导化疗的中国急性髓系白血病(AML)患者中的疗效及安全性。 方法: 一项Ⅲ期随机、双盲安慰剂对照试验(VIALE-C)中中国队列的结果。在本项国际临床试验中,入组了不适合接受强化化疗、新诊断为AML的18岁或以上的成人患者。在全球范围内,患者(211例)按2∶1的比例随机分配接受Venetoclax+LDAC或安慰剂+LDAC(28 d为1个周期),在第1~10天接受LDAC。主要研究终点为总生存(OS);次要研究终点包括缓解率、无事件生存期及不良事件(AE)。 结果: 入组15例中国患者(Venetoclax组9例;安慰剂组6例)。中位年龄为72(61~86)岁。与安慰剂组相比,Venetoclax组的死亡风险下降38%(HR=0.62,95%CI 0.12~3.07)。对延长6个月随访进行的计划外分析显示,Venetoclax组的中位OS时间为9.0个月,安慰剂组为4.1个月。完全缓解(CR)率与血细胞计数未完全恢复的CR(CRi)率分别为33%(3/9)和0(0/6)。最常见的非血液学AE(Venetoclax组与安慰剂组)为低钾血症(5/9和4/6)、呕吐(4/9和3/6)、便秘(2/9和4/6)和低白蛋白血症(1/9和4/6)。 结论: Venetoclax联合LDAC在中国患者中表现出有意义的疗效和可管理的安全性特征,这与在全球VIALE-C人群中的观察结果一致,使其成为不适合接受强化化疗的新诊断AML患者的一个重要治疗选择。.
引用
- Hu Y, Jin J, Zhang Y, et al. [Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 33979972. doi:10.3760/cma.j.issn.0253-2727.2021.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。